109 related articles for article (PubMed ID: 21844496)
1. Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.
Piha-Paul SA; Cohen PR; Kurzrock R
J Clin Oncol; 2011 Sep; 29(26):e727-30. PubMed ID: 21844496
[No Abstract] [Full Text] [Related]
2. How many therapeutic options are there for recurrent or metastatic salivary duct carcinoma?
Locati LD; Bossi P; Licitra L
J Clin Oncol; 2012 Feb; 30(6):672; author reply 672-673. PubMed ID: 22253461
[No Abstract] [Full Text] [Related]
3. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.
Ekshyyan O; Mills GM; Lian T; Amirghahari N; Rong X; Lowery-Nordberg M; Abreo F; Veillon DM; Caldito G; Speicher L; Glass J; Nathan CO
Head Neck; 2010 Dec; 32(12):1619-28. PubMed ID: 20222045
[TBL] [Abstract][Full Text] [Related]
4. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
5. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
Wang X; Zhan Y; Zhao L; Alvarez J; Chaudhary I; Zhou BB; Abraham RT; Feuerstein GZ
J Pharmacol Exp Ther; 2011 Nov; 339(2):421-9. PubMed ID: 21835932
[TBL] [Abstract][Full Text] [Related]
6. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
Bukowski RM
Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
[No Abstract] [Full Text] [Related]
7. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
[No Abstract] [Full Text] [Related]
8. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.
Piha-Paul SA; Hong DS; Kurzrock R
J Clin Oncol; 2011 Apr; 29(12):e333-5. PubMed ID: 21263090
[No Abstract] [Full Text] [Related]
9. Temsirolimus for metastatic desmoplastic small round cell tumor.
Thijs AM; van der Graaf WT; van Herpen CM
Pediatr Blood Cancer; 2010 Dec; 55(7):1431-2. PubMed ID: 20730888
[TBL] [Abstract][Full Text] [Related]
10. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
Mounier N; Vignot S; Spano JP
Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
[TBL] [Abstract][Full Text] [Related]
11. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors.
Jedlickova Z; Burlakova I; Bug G; Baurmann H; Schwerdtfeger R; Schleuning M
Biol Blood Marrow Transplant; 2011 May; 17(5):657-63. PubMed ID: 20696263
[TBL] [Abstract][Full Text] [Related]
12. [Antihormonal therapy in breast cancer and mTOR inhibitors].
Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T
Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994
[TBL] [Abstract][Full Text] [Related]
13. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP; Kistler AD; Serra AL
Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
[TBL] [Abstract][Full Text] [Related]
14. Temsirolimus, the mTOR inhibitor, induces autophagy in adenoid cystic carcinoma: in vitro and in vivo.
Liu W; Huang S; Chen Z; Wang H; Wu H; Zhang D
Pathol Res Pract; 2014 Nov; 210(11):764-9. PubMed ID: 24767255
[TBL] [Abstract][Full Text] [Related]
15. Temsirolimus.
Stock C; Zaccagnini M; Schulze M; Teber D; Rassweiler JJ
Recent Results Cancer Res; 2010; 184():189-97. PubMed ID: 20072839
[TBL] [Abstract][Full Text] [Related]
16. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
17. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.
Errasti P; Izquierdo D; Martín P; Errasti M; Slon F; Romero A; Lavilla FJ
Transplant Proc; 2010 Oct; 42(8):3053-4. PubMed ID: 20970608
[TBL] [Abstract][Full Text] [Related]
18. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.
García-Echeverría C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4308-12. PubMed ID: 20561789
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
De Masson A; Fouchard N; Méry-Bossard L; Dauendorffer JN
Dermatology; 2011; 223(1):4-8. PubMed ID: 21846963
[TBL] [Abstract][Full Text] [Related]
20. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
